Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 567

1.

Therapie des Antiphospholipid-Syndroms (APS) mit DOAKs.

Bauersachs R, Schellong S, Stücker M, Oldenburg J, Kalka C, Scholz U, Lindhoff-Last E.

Hamostaseologie. 2019 Aug 12. doi: 10.1055/s-0039-1694789. [Epub ahead of print] German. No abstract available.

PMID:
31404932
2.

Structure functional insights into calcium binding during the activation of coagulation factor XIII A.

Singh S, Dodt J, Volkers P, Hethershaw E, Philippou H, Ivaskevicius V, Imhof D, Oldenburg J, Biswas A.

Sci Rep. 2019 Aug 5;9(1):11324. doi: 10.1038/s41598-019-47815-z.

3.

Increased Activated Protein C Response Rates Reduce the Thrombotic Risk of Factor V Leiden Carriers But Not of Prothrombin 20210G>A Carriers.

Rühl H, Berens C, Winterhagen FI, Reda S, Müller J, Oldenburg J, Pötzsch B.

Circ Res. 2019 Aug 16;125(5):523-534. doi: 10.1161/CIRCRESAHA.119.315037. Epub 2019 Jul 17.

PMID:
31314700
4.

Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program.

Lissitchkov T, Klukowska A, Pasi J, Kessler CM, Klamroth R, Liesner RJ, Belyanskaya L, Walter O, Knaub S, Bichler J, Jansen M, Oldenburg J.

Ther Adv Hematol. 2019 Jun 26;10:2040620719858471. doi: 10.1177/2040620719858471. eCollection 2019. Review.

5.

Activity Pattern Analysis Indicates Increased but Balanced Systemic Coagulation Activity in Response to Surgical Trauma.

Friedrich MJ, Schmolders J, Rommelspacher Y, Strauss A, Rühl H, Mayer G, Oldenburg J, Wirtz DC, Müller J, Pötzsch B.

TH Open. 2018 Oct 1;2(4):e350-e356. doi: 10.1055/s-0038-1673390. eCollection 2018 Oct.

6.

Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A.

Müller J, Pekrul I, Pötzsch B, Berning B, Oldenburg J, Spannagl M.

Thromb Haemost. 2019 Jun 16. doi: 10.1055/s-0039-1692427. [Epub ahead of print]

PMID:
31203578
7.

Metacognitive functioning in bipolar disorder versus controls and its correlations with neurocognitive functioning in a cross-sectional design.

Van Camp L, Sabbe BGC, Oldenburg JFE.

Compr Psychiatry. 2019 Jul;92:7-12. doi: 10.1016/j.comppsych.2019.06.001. Epub 2019 Jun 6.

8.

Impact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic Review.

Williams SB, Ray-Zack MD, Hudgins HK, Oldenburg J, Trinh QD, Nguyen PL, Shore ND, Wirth MP, O'Brien T, Catto JWF.

Eur Urol Oncol. 2019 May;2(3):265-273. doi: 10.1016/j.euo.2018.10.006. Epub 2018 Nov 5. Review.

PMID:
31200840
9.

Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A.

Bachelet D, Albert T, Mbogning C, Hässler S, Zhang Y, Schultze-Strasser S, Repessé Y, Rayes J, Pavlova A, Pezeshkpoor B, Liphardt K, Davidson JE, Hincelin-Méry A, Dönnes P, Lacroix-Desmazes S, Königs C, Oldenburg J, Broët P; ABIRISK consortium.

PLoS One. 2019 Jun 13;14(6):e0218258. doi: 10.1371/journal.pone.0218258. eCollection 2019.

10.

F8 Inversions at Xq28 Causing Hemophilia A Are Associated With Specific Methylation Changes: Implication for Molecular Epigenetic Diagnosis.

Jamil MA, Sharma A, Nuesgen N, Pezeshkpoor B, Heimbach A, Pavlova A, Oldenburg J, El-Maarri O.

Front Genet. 2019 May 29;10:508. doi: 10.3389/fgene.2019.00508. eCollection 2019.

11.

Identification of Potential Novel Interacting Partners for Coagulation Factor XIII B (FXIII-B) Subunit, a Protein Associated with a Rare Bleeding Disorder.

Singh S, Akhter MS, Dodt J, Volkers P, Reuter A, Reinhart C, Krettler C, Oldenburg J, Biswas A.

Int J Mol Sci. 2019 May 31;20(11). pii: E2682. doi: 10.3390/ijms20112682.

12.

Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study.

Oldenburg J, Hay CRM, Jiménez-Yuste V, Peyvandi F, Schved JF, Szamosi J, Winding B, Lethagen S.

BMJ Open. 2019 May 30;9(5):e028012. doi: 10.1136/bmjopen-2018-028012.

13.

The role of variant alleles of the mannose-binding lectin in the inhibitor development in severe hemophilia A.

Ulrich-Merzenich G, Hausen A, Zeitler H, Goldmann G, Oldenburg J, Pavlova A.

Thromb Res. 2019 Jul;179:140-146. doi: 10.1016/j.thromres.2019.05.005. Epub 2019 May 9.

PMID:
31141731
14.

Estimation of Nuwiq® (simoctocog alfa) activity using one-stage and chromogenic assays-Results from an international comparative field study.

Tiefenbacher S, Albisetti M, Baker P, Kappert G, Kitchen S, Kremer Hovinga JA, Pouplard C, Scholz U, Ternisien C, Borgvall C, Vicente T, Belyanskaya L, Walter O, Oldenburg J; Nuwiq Field Study Participating Laboratories.

Haemophilia. 2019 Jul;25(4):708-717. doi: 10.1111/hae.13763. Epub 2019 May 20.

PMID:
31106957
15.

Early experiences with PD-1 inhibitor treatment of platinum resistant epithelial ovarian cancer.

Normann MC, Türzer M, Diep LM, Oldenburg J, Gajdzik B, Solheim O, Rud E.

J Gynecol Oncol. 2019 Jul;30(4):e56. doi: 10.3802/jgo.2019.30.e56. Epub 2019 Feb 27.

16.

Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII.

Kearney S, Raffini LJ, Pham TP, Lee XY, von Mackensen S, Landorph A, Takedani H, Oldenburg J.

Patient Prefer Adherence. 2019 Apr 9;13:497-513. doi: 10.2147/PPA.S196103. eCollection 2019.

17.

The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab.

Carcao M, Escuriola-Ettingshausen C, Santagostino E, Oldenburg J, Liesner R, Nolan B, Bátorová A, Haya S, Young G; Future of Immunotolerance Treatment Group.

Haemophilia. 2019 Jul;25(4):676-684. doi: 10.1111/hae.13762. Epub 2019 Apr 29.

PMID:
31033112
18.

[Leitlinie der Gesellschaft für Thrombose- und Hämostaseforschung (GTH) zur Struktur- und Prozessqualität von Hämophilie-Zentren].

Eichler H, Pedroni MA, Halimeh S, Königs C, Langer F, Miesbach W, Oldenburg J, Scholz U, Streif W, Klamroth R.

Hamostaseologie. 2019 Apr 24. doi: 10.1055/s-0039-1688450. [Epub ahead of print] German. No abstract available.

PMID:
31018219
19.

Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS).

Mahlangu J, Oldenburg J, Callaghan MU, Shima M, Mancuso ME, Trask P, Recht M, Garcia C, Yang R, Lehle M, Macharia H, Asikanius E, Levy GG, Kruse-Jarres R, von Mackensen S.

Haemophilia. 2019 May;25(3):382-391. doi: 10.1111/hae.13731. Epub 2019 Apr 24.

PMID:
31016855
20.

Disruption of Structural Disulfides of Coagulation FXIII-B Subunit; Functional Implications for a Rare Bleeding Disorder.

Singh S, Akhter MS, Dodt J, Sharma A, Kaniyappan S, Yadegari H, Ivaskevicius V, Oldenburg J, Biswas A.

Int J Mol Sci. 2019 Apr 22;20(8). pii: E1956. doi: 10.3390/ijms20081956.

21.

In silico and in vitro evaluation of the impact of mutations in non-severe haemophilia A patients on assay discrepancies.

Pezeshkpoor B, Gazorpak M, Berkemeier AC, Singer H, Pavlova A, Biswas A, Oldenburg J.

Ann Hematol. 2019 Aug;98(8):1855-1865. doi: 10.1007/s00277-019-03691-1. Epub 2019 Apr 17.

PMID:
30997536
22.

Correction to: Identification of novel mutations in congenital afibrinogenemia patients and molecular modeling of missense mutations in Pakistani population.

Naz A, Biswas A, Khan TN, Goodeve A, Ahmed N, Saqlain N, Ahmed S, Ujjan ID, Shamsi TS, Oldenburg J.

Thromb J. 2019 Apr 4;17:5. doi: 10.1186/s12959-019-0193-9. eCollection 2019.

23.

Detailed methylation map of LINE-1 5'-promoter region reveals hypomethylated CpG hotspots associated with tumor tissue specificity.

Sharma A, Jamil MA, Nuesgen N, Dauksa A, Gulbinas A, Schulz WA, Oldenburg J, El-Maarri O.

Mol Genet Genomic Med. 2019 May;7(5):e601. doi: 10.1002/mgg3.601. Epub 2019 Apr 6.

24.

Exploring the structural similarity yet functional distinction between coagulation factor XIII-B and complement factor H sushi domains.

Akhter MS, Singh S, Yadegari H, Ivaskevicius V, Oldenburg J, Biswas A.

J Thromb Thrombolysis. 2019 Jul;48(1):95-102. doi: 10.1007/s11239-019-01841-w.

PMID:
30915671
25.

Coagulation Factor XIIIa Inhibitor Tridegin: On the Role of Disulfide Bonds for Folding, Stability, and Function.

Bäuml CA, Schmitz T, Paul George AA, Sudarsanam M, Hardes K, Steinmetzer T, Holle LA, Wolberg AS, Pötzsch B, Oldenburg J, Biswas A, Imhof D.

J Med Chem. 2019 Apr 11;62(7):3513-3523. doi: 10.1021/acs.jmedchem.8b01982. Epub 2019 Mar 21.

PMID:
30852892
26.

Transcriptome-wide analysis of filarial extract-primed human monocytes reveal changes in LPS-induced PTX3 expression levels.

Buerfent BC, Gölz L, Hofmann A, Rühl H, Stamminger W, Fricker N, Hess T, Oldenburg J, Nöthen MM, Schumacher J, Hübner MP, Hoerauf A.

Sci Rep. 2019 Feb 22;9(1):2562. doi: 10.1038/s41598-019-38985-x.

27.

Rapid and sustained immune tolerance to inhibitors induced by a plasma-derived, VWF-containing FVIII concentrate.

Santagostino E, Rangarajan S, Oldenburg J, Peiró-Jordan R, Jiménez-Yuste V.

Haemophilia. 2019 Mar;25(2):e110-e113. doi: 10.1111/hae.13676. Epub 2019 Feb 20. No abstract available.

PMID:
30786119
28.

Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting.

Kruse-Jarres R, Oldenburg J, Santagostino E, Shima M, Kempton CL, Kessler CM, Lehle M, Chebon S, Selak Bienz N, Asikanius E, Mahlangu J.

Haemophilia. 2019 Mar;25(2):213-220. doi: 10.1111/hae.13655. Epub 2019 Feb 6.

PMID:
30724422
29.

Prevalence of Obesity in Young Patients with Severe Haemophilia and Its Potential Impact on Factor VIII Consumption in Germany.

Olivieri M, Königs C, Heller C, Horneff S, Oldenburg J, Halimeh S, Kentouche K, Knöfler R, Fischer L, Pfrepper C, Kurnik K, Bidlingmaier C.

Hamostaseologie. 2019 Feb 5. doi: 10.1055/s-0039-1677874. [Epub ahead of print]

PMID:
30722069
30.

Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A.

Repessé Y, Costa C, Palla R, Moshai EF, Borel-Derlon A, D'Oiron R, Rothschild C, El-Beshlawy A, Elalfy M, Ramanan V, Eshghi P, Oldenburg J, Pavlova A, Rosendaal FR, Peyvandi F, Kaveri SV, Lacroix-Desmazes S.

Haematologica. 2019 Aug;104(8):e369-e372. doi: 10.3324/haematol.2018.212001. Epub 2019 Jan 31. No abstract available.

31.

Acute Hepatitis E Virus infection in a hemophilic patient with acquired inhibitor during immune tolerance therapy according to modified Bonn-Malmö protocol.

Schlabe S, van Bremen K, Goldmann G, Oldenburg J, Eis-Hübinger AM, Zeitler H, Spengler U.

Haemophilia. 2019 Mar;25(2):e117-e120. doi: 10.1111/hae.13688. Epub 2019 Jan 29. No abstract available.

PMID:
30694010
32.

Impact of Telemedicine Tools on Record Keeping and Compliance in Haemophilia Care.

Banchev A, Goldmann G, Marquardt N, Klein C, Horneff S, Langenkamp R, Frankenberger T, Oldenburg J.

Hamostaseologie. 2019 Jan 17. doi: 10.1055/s-0038-1676128. [Epub ahead of print]

PMID:
30654393
33.

The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH.

Makris M, Oldenburg J, Mauser-Bunschoten EP, Peerlinck K, Castaman G, Fijnvandraat K; subcommittee on Factor VIII, Factor IX and Rare Bleeding Disorders.

J Thromb Haemost. 2018 Dec;16(12):2530-2533. doi: 10.1111/jth.14315. Epub 2018 Nov 15. No abstract available.

PMID:
30430726
34.

The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.

Oldenburg J, Mahlangu JN, Bujan W, Trask P, Callaghan MU, Young G, Asikanius E, Peyvandi F, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Xu J, Windyga J, Shima M, von Mackensen S.

Haemophilia. 2019 Jan;25(1):33-44. doi: 10.1111/hae.13618. Epub 2018 Nov 14.

35.

Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.

Lentz SR, Janic D, Kavakli K, Miljic P, Oldenburg J, C Ozelo M, Santagostino E, Suzuki T, Zupancic Šalek S, Korsholm L, Matytsina I, Tiede A.

Haemophilia. 2018 Nov;24(6):e391-e394. doi: 10.1111/hae.13617. Epub 2018 Nov 6.

PMID:
30402994
36.

Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study.

Mahlangu J, Oldenburg J, Callaghan MU, Shima M, Santagostino E, Moore M, Recht M, Garcia C, Yang R, Lehle M, Macharia H, Asikanius E, Levy GG, Kruse-Jarres R.

Haemophilia. 2018 Nov;24(6):921-929. doi: 10.1111/hae.13612. Epub 2018 Oct 8.

PMID:
30295389
37.

The importance of inhibitor eradication in clinically complicated hemophilia A patients.

Oldenburg J, Young G, Santagostino E, Escuriola Ettingshausen C.

Expert Rev Hematol. 2018 Nov;11(11):857-862. doi: 10.1080/17474086.2018.1521718. Epub 2018 Oct 4. Review.

PMID:
30286680
38.

First Case of Laparoscopic Mini-Gastric Bypass for the Treatment of Morbid Obesity in Severe Haemophilia A.

Plamper A, Goldmann G, Lingohr P, Horneff S, Dohmen J, Oldenburg J, Rheinwalt KP.

Hamostaseologie. 2019 Jun;39(2):208-210. doi: 10.1055/s-0038-1668571. Epub 2018 Sep 24. No abstract available.

PMID:
30248701
39.

Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials.

Oldenburg J, Carcao M, Lentz SR, Mahlangu J, Mancuso ME, Matsushita T, Négrier C, Clausen WHO, Ehrenforth S, Young G.

Haemophilia. 2018 Nov;24(6):911-920. doi: 10.1111/hae.13608. Epub 2018 Sep 24.

PMID:
30248217
40.

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.

Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, Schmitt C, Jiménez-Yuste V, Kempton C, Dhalluin C, Callaghan MU, Bujan W, Shima M, Adamkewicz JI, Asikanius E, Levy GG, Kruse-Jarres R.

N Engl J Med. 2018 Aug 30;379(9):811-822. doi: 10.1056/NEJMoa1803550.

41.

The longitudinal course of cognitive insight and mood in bipolar disorder.

Van Camp L, van den Ameele S, Sabbe BGC, Oldenburg JFE.

Psychiatry Res. 2018 Nov;269:9-12. doi: 10.1016/j.psychres.2018.08.063. Epub 2018 Aug 17.

PMID:
30144670
42.

ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up.

Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, Clarke N, Cohn-Cedermark G, Daugaard G, Dieckmann KP, Fizazi K, Fosså S, Germa-Lluch JR, Giannatempo P, Gietema JA, Gillessen S, Haugnes HS, Heidenreich A, Hemminki K, Huddart R, Jewett MAS, Joly F, Lauritsen J, Lorch A, Necchi A, Nicolai N, Oing C, Oldenburg J, Ondruš D, Papachristofilou A, Powles T, Sohaib A, Ståhl O, Tandstad T, Toner G, Horwich A.

Ann Oncol. 2018 Aug 1;29(8):1658-1686. doi: 10.1093/annonc/mdy217.

PMID:
30113631
43.

Type-3 von Willebrand disease in India-Clinical spectrum and molecular profile.

Elayaperumal S, Fouzia NA, Biswas A, Nair SC, Viswabandya A, George B, Abraham A, Oldenburg J, Edison ES, Srivastava A.

Haemophilia. 2018 Nov;24(6):930-940. doi: 10.1111/hae.13542. Epub 2018 Jul 8.

PMID:
29984440
44.

Impact of interleukin 6 promoter polymorphisms (-174 G > C, -572 G > C and -597 G > A) on plasma IL-6 levels and their influence on the development of DVT: a study from India.

Sharma A, Singh K, Biswas A, Ranjan R, Kishor K, Pandey H, Kumar R, Mahapatra M, Oldenburg J, Saxena R.

Hematology. 2018 Dec;23(10):833-838. doi: 10.1080/10245332.2018.1483546. Epub 2018 Jun 11.

PMID:
29890913
45.

Long-term serum platinum changes and their association with cisplatin-related late effects in testicular cancer survivors.

Hjelle LV, Gundersen POM, Hellesnes R, Sprauten M, Brydøy M, Tandstad T, Wilsgaard T, Fosså SD, Oldenburg J, Bremnes RM, Haugnes HS.

Acta Oncol. 2018 Oct;57(10):1392-1400. doi: 10.1080/0284186X.2018.1473641. Epub 2018 May 18.

PMID:
29775128
46.

Users' Perspectives on mHealth Self-Management of Bipolar Disorder: Qualitative Focus Group Study.

Switsers L, Dauwe A, Vanhoudt A, Van Dyck H, Lombaerts K, Oldenburg J.

JMIR Mhealth Uhealth. 2018 May 2;6(5):e108. doi: 10.2196/mhealth.9529.

47.

SOCS1 and SOCS3 Target IRF7 Degradation To Suppress TLR7-Mediated Type I IFN Production of Human Plasmacytoid Dendritic Cells.

Yu CF, Peng WM, Schlee M, Barchet W, Eis-Hübinger AM, Kolanus W, Geyer M, Schmitt S, Steinhagen F, Oldenburg J, Novak N.

J Immunol. 2018 Jun 15;200(12):4024-4035. doi: 10.4049/jimmunol.1700510. Epub 2018 Apr 30.

48.

Re: Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

Heinrich D, Russnes KM, Oldenburg J.

Eur Urol. 2018 Aug;74(2):236-237. doi: 10.1016/j.eururo.2018.04.010. Epub 2018 Apr 22. No abstract available.

PMID:
29691083
49.

VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites.

Czogalla KJ, Liphardt K, Höning K, Hornung V, Biswas A, Watzka M, Oldenburg J.

Blood Adv. 2018 Mar 27;2(6):691-702. doi: 10.1182/bloodadvances.2017006775.

50.

In vivo thrombin generation and subsequent APC formation are increased in factor V Leiden carriers.

Rühl H, Winterhagen FI, Berens C, Müller J, Oldenburg J, Pötzsch B.

Blood. 2018 Mar 29;131(13):1489-1492. doi: 10.1182/blood-2017-12-823831. Epub 2018 Feb 21. No abstract available.

Supplemental Content

Loading ...
Support Center